These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8726036)

  • 1. Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model.
    Garrison MW; Malone CL; Eiland JE
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1545-7. PubMed ID: 8726036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
    Liu P; Rand KH; Obermann B; Derendorf H
    Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of once-daily versus twice-daily administration of cefdinir against typical bacterial respiratory tract pathogens.
    Ross GH; Hovde LB; Ibrahim KH; Ibrahim YH; Rotschafer JC
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2936-8. PubMed ID: 11557496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activities of trospectomycin, cefpodoxime, and second-generation cephalosporins against Haemophilus influenzae type b.
    LiPuma JJ; Daley B; Stull TL
    J Antimicrob Chemother; 1990 Apr; 25(4):535-9. PubMed ID: 2141018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Activity of cefpodoxime and other oral beta-lactams against Haemophilus influenzae and Streptococcus pneumoniae with different susceptibilities to penicillin].
    Fenoll A; Robledo O; Lerma M; Giménez MJ; Cebrián L; Casal J; Aguilar L; Gómez-Lus ML
    Rev Esp Quimioter; 2006 Mar; 19(1):39-44. PubMed ID: 16688290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third generation oral cephalosporins: comparative in vitro kinetics.
    Speciale A; Blandino G; Nicoletti G
    J Chemother; 1995 May; 7 Suppl 1():9-12. PubMed ID: 8618112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
    Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME
    Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
    Xiao YH; Gao L; Li Y; Lü Y; Liu J; Liu Y
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1867-71. PubMed ID: 15631795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with cefpodoxime proxetil in acute otitis media.
    Cohen R
    Pediatr Infect Dis J; 1995 Apr; 14(4 Suppl):S12-8. PubMed ID: 7792125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of simulated total versus free-drug serum concentrations of a low versus a high protein bound third-generation oral cephalosporin (Cefpodoxime versus cefditoren) against Streptococcus pneumoniae.
    Echeverria O; Alou L; Sevillano D; Gonzalez N; Gomez-Lus ML; Aguilar L; Prieto J
    J Chemother; 2007 Jun; 19(3):288-94. PubMed ID: 17594924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
    Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
    J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of cefpodoxime against pathogens responsible for community-acquired respiratory tract infections.
    Dabernat H; Avril JL; Boussougant Y
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():1-6. PubMed ID: 2127267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antimicrobial activities of cefetamet against clinically isolated strains from community acquired respiratory tract infections. Part III].
    Matsumoto Y; Ishihara R; Suzuki Y; Nishinari C; Ishii Y; Nakane Y; Endo H
    Jpn J Antibiot; 1999 Jun; 52(6):469-77. PubMed ID: 10481811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inoculum effect and bactericidal activity of cefditoren and other antibiotics against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis.
    Soriano F; Coronel P; Gimeno M; Jiménez M; García-Corbeira P; Fernández-Roblas R
    Eur J Clin Microbiol Infect Dis; 1996 Sep; 15(9):761-3. PubMed ID: 8922582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM; Suter M; Borsos S
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity.
    Mori N; Kodama T; Sakai A; Suzuki T; Sugihara T; Yamaguchi S; Nishijima T; Aoki A; Toriya M; Kasai M; Hatano S; Kitagawa M; Yoshimi A; Nishimura K
    Int J Antimicrob Agents; 2001 Nov; 18(5):451-61. PubMed ID: 11711261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of the bactericidal effect of cefpodoxime using an in vitro pharmacokinetic model].
    Caisson A; Chantot JF
    Pathol Biol (Paris); 1991 Oct; 39(8):774-9. PubMed ID: 1762835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA; Farrell DJ; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.